THERAVANCE BIOPHARMA Reports Positive Earnings Results for Q2 of FY2023
August 17, 2023
☀️Earnings Overview
On June 30 2023, THERAVANCE BIOPHARMA ($NASDAQ:TBPH) announced their second quarter of FY2023 earnings results. With total revenue of USD 13.8 million, a 24.4% increase year-over-year, the company reported a net loss of -15.6 million for the quarter, compared to the loss of -8.2 million in the same period of the prior year.
Share Price
On Monday, THERAVANCE BIOPHARMA reported its positive earnings results for the second quarter of FY2023. The stock opened at $10.0 but closed at $9.8, down 1.2% from its previous closing price of $10.0. Furthermore, THERAVANCE BIOPHARMA also announced that they have received approval from the FDA for their new drug, Yupelri, which is used to treat moderate to severe chronic obstructive pulmonary disease (COPD). This will further strengthen THERAVANCE BIOPHARMA’s financial standing and help them remain profitable in the upcoming quarters. Overall, the strong earnings results from THERAVANCE BIOPHARMA demonstrate that the pharmaceutical company is well-positioned to weather any economic downturn due to the pandemic.
Additionally, with the approval of Yupelri and continued success of Revefenacin, THERAVANCE BIOPHARMA is expected to remain profitable in the coming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Theravance Biopharma. More…
| Total Revenues | Net Income | Net Margin |
| 51.27 | 868.54 | -187.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Theravance Biopharma. More…
| Operations | Investing | Financing |
| -172.14 | 1.15k | -758.81 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Theravance Biopharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 446.63 | 166.47 | 6.41 |
Key Ratios Snapshot
Some of the financial key ratios for Theravance Biopharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -12.6% | – | -218.3% |
| FCF Margin | ROE | ROA |
| -338.2% | -18.9% | -15.7% |
Analysis
At GoodWhale, we believe that it is important for investors to have access to detailed information about the companies they are considering investing in. That is why we are here to help you analyze the financials of THERAVANCE BIOPHARMA. Our Risk Rating system has determined that THERAVANCE BIOPHARMA is a medium risk investment in terms of financial and business aspects. In order to help give you a better understanding of the company’s financial health, GoodWhale has detected two risk warnings in the balance sheet and financial journal. To get access to this valuable information, simply register on GoodWhale.com. From there, you can view all the data we have collected and use it to make a more informed decision when choosing which stocks to invest in. More…
Peers
The Company focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas. Its programs include VIBATIV (telavancin), ANORO Ellipta, REYVOW, TD-1473 and others. The company’s competitors include Cerevel Therapeutics Holdings Inc, Viracta Therapeutics Inc, Island Pharmaceuticals Ltd.
– Cerevel Therapeutics Holdings Inc ($NASDAQ:CERE)
Cerevel Therapeutics Holdings Inc is a biopharmaceutical company that focuses on the treatment of neurological and psychiatric disorders. The company has a market cap of 4.26B as of 2022 and a return on equity of -36.45%. Cerevel Therapeutics Holdings Inc’s products include treatments for disorders such as Alzheimer’s disease, Parkinson’s disease, and schizophrenia. The company’s products are approved by the US Food and Drug Administration and are marketed in the United States and Europe.
– Viracta Therapeutics Inc ($NASDAQ:VIRX)
Viracta Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for virally-associated cancers. The company’s lead product candidate is VAL-083, which is being evaluated in a Phase III clinical trial in glioblastoma. Viracta also has a pipeline of other product candidates in various stages of development. The company’s market cap is $149.48M as of 2022 and its ROE is -57.78%.
– Island Pharmaceuticals Ltd ($ASX:ILA)
Island Pharmaceuticals Ltd is a pharmaceutical company with a market cap of 12.6M as of 2022. The company has a Return on Equity of 2.61%. Island Pharmaceuticals Ltd is a pharmaceutical company that manufactures and sells pharmaceutical products. The company’s products include prescription and over-the-counter drugs, vitamins, and herbal supplements.
Summary
THERAVANCE BIOPHARMA‘s second quarter of fiscal 2023 was a mixed bag for investors. While total revenue grew 24.4% to $13.8 million, net income fell to -$15.6 million from -$8.2 million in the same period of the prior year. Analysts will be carefully monitoring the company’s progress going forward, as it works to increase profitability.
Investors should also pay attention to the company’s development pipeline, which includes several potential new drugs in late-stage clinical trials. This could be a key indicator of the company’s long-term success.
